ClearBridge Investments released its second-quarter 2025 investor letter, noting a 10.9% return on US equities and 18.2% on the Russell Midcap Growth Index. The “mid cap plus” segment performed well in IT, industrials, and financials, outperforming the benchmark. Check out the fund’s top five holdings for 2025 picks.

In the same letter, ClearBridge Growth Strategy highlighted Charles River Laboratories International, Inc. (CRL), a company offering drug discovery and safety testing services. CRL stock showed a 5.00% one-month return and gained 26.44% over 52 weeks, closing at $151.60 per share on September 16, 2025.

ClearBridge Growth Strategy’s investor letter discussed closing out of MongoDB and CRL due to challenges in the biotech funding environment and regulatory risks. While activist interest in CRL exists, potential regulatory changes could impact future revenue streams.

According to data, 49 hedge fund portfolios held Charles River Laboratories International, Inc. (CRL) at the end of Q2 2025, up from 39 in the previous quarter. CRL reported $1.03 billion in revenue, a 0.6% increase from Q2 2024. Consider AI stocks for greater upside potential with less downside risk.

Read more at Yahoo Finance: Here’s Why ClearBridge Investments Growth Strategy Closed Out Charles River Laboratories International (CRL)